DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brunelle, A.
Right arrow Articles by Cashman, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brunelle, A.
Right arrow Articles by Cashman, J.

0090-9556/97/2508-1001-1007$02.00/0
DRUG METABOLISM AND DISPOSITION
Copyright © 1997 by The American Society for Pharmacology and Experimental Therapeutics
Vol. 25, No. 8

Characterization of Two Human Flavin-Containing Monooxygenase (Form 3) Enzymes Expressed in Escherichia coli as Maltose Binding Protein Fusions

Alan Brunelle, Yi-An Bi, Jing Lin, Brett Russell, Lisa Luy, Clifford Berkman, and John Cashman

Seattle Biomedical Research Institute

To examine the possibility for drug metabolism polymorphism, adult human flavin-containing monooxygenases (form 3) (EC 1.14.13.8) that differ at one amino acid were expressed in Escherichia coli as maltose binding protein fusions. The cDNA that was first reported during the cloning of adult human flavin-containing monooxygenase was designated the wild type lys158 enzyme. A second cDNA has been identified as a common polymorphism in some human populations and was designated the glu158 enzyme. The cDNA that encodes both enzymes was subcloned into a high yield protein fusion expression system, expressed, and the protein was partially purified by affinity chromatography and characterized for enzyme activity with selective functional substrate probes. N- and S-oxygenation activity of both enzymes was determined with 10-(N,N-dimethylaminopentyl)-2-(trifluoromethyl)phenothiazine and methyl p-tolyl sulfide, respectively. It was found that expression of both lys158 and glu158 enzymes of the human flavin-containing monooxygenase form 3 as fusions with the maltose binding protein resulted in an enzyme that was soluble and greatly stabilized and had a reduced requirement for detergent during enzyme purification and during the assay for activity. Expression of the fusion proteins has allowed the preparation of stable and highly active enzyme at greater purity than was readily possible in the past. With the exception of the stability and solubility characteristics, the physical and chemical properties of lys158 and glu158 maltose binding fusion proteins of human flavin-containing monooxygenase form 3 variants resembled that of flavin-containing monooxygenase enzyme activity associated with human liver microsomes and enzyme isolated from a previous Escherichia coli expression system that lacked the protein fusion. Comparison of the catalytic activity of the two fusion proteins showed that while both forms were active, there were differences in their substrate specificities. Expression of the adult human flavin-containing monooxygenase form 3 as a maltose binding protein has allowed considerable advances over the previously reported cDNA-expressed enzyme systems and may provide the basis for examining the role of the flavin-containing monooxygenase in human xenobiotic or drug metabolism.


Copyright © 1997 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
T. Borbas, J. Zhang, M. A. Cerny, I. Liko, and J. R. Cashman
Investigation of Structure and Function of a Catalytically Efficient Variant of the Human Flavin-Containing Monooxygenase Form 3
Drug Metab. Dispos., December 1, 2006; 34(12): 1995 - 2002.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
V. Lattard, J. Zhang, and J. R. Cashman
Alternative Processing Events in Human FMO Genes
Mol. Pharmacol., June 1, 2004; 65(6): 1517 - 1525.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
J. R. Cashman, V. Lattard, and J. Lin
EFFECT OF TOTAL PARENTERAL NUTRITION AND CHOLINE ON HEPATIC FLAVIN-CONTAINING AND CYTOCHROME P-450 MONOOXYGENASE ACTIVITY IN RATS
Drug Metab. Dispos., February 1, 2004; 32(2): 222 - 229.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
V. Lattard, J. Zhang, Q. Tran, B. Furnes, D. Schlenk, and J. R. Cashman
TWO NEW POLYMORPHISMS OF THE FMO3 GENE IN CAUCASIAN AND AFRICAN-AMERICAN POPULATIONS: COMPARATIVE GENETIC AND FUNCTIONAL STUDIES
Drug Metab. Dispos., July 1, 2003; 31(7): 854 - 860.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
Y. Zhao, S. K. Christensen, C. Fankhauser, J. R. Cashman, J. D. Cohen, D. Weigel, and J. Chory
A Role for Flavin Monooxygenase-Like Enzymes in Auxin Biosynthesis
Science, January 12, 2001; 291(5502): 306 - 309.
[Abstract] [Full Text]


Home page
Drug Metab. Dispos.Home page
J. R. Cashman, B. R. Akerman, S. M. Forrest, and E. P. Treacy
Population-Specific Polymorphisms of the Human FMO3 Gene: Significance for Detoxication
Drug Metab. Dispos., February 1, 2000; 28(2): 169 - 173.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
J. R. Cashman, Y. N. Xiong, L. Xu, and A. Janowsky
N-Oxygenation of Amphetamine and Methamphetamine by the Human Flavin-Containing Monooxygenase (Form 3): Role in Bioactivation and Detoxication
J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 1251 - 1260.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.